Ivan Gentile1, Antonio Riccardo Buonomo2, Riccardo Scotto1, Emanuela Zappulo1, Canio Carriero1, Mauro Piccirillo3, Francesco Izzo3, Marianna Rizzo4, Dionigio Cerasuolo4, Guglielmo Borgia1, Ernesta Cavalcanti4. 1. Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy. 2. Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy antonioriccardobuonomo@gmail.com. 3. Division of Abdominal Surgical Oncology, Hepatobiliary Unit, "Fondazione G. Pascale" National Cancer Institute, IRCCS, Naples, Italy. 4. Division of Laboratory Medicine, "Fondazione G. Pascale" National Cancer Institute, IRCCS, Naples, Italy.
Abstract
BACKGROUND/AIM: Patients affected by liver cirrhosis are at high risk for developing hepatocellular carcinoma (HCC). The aim of this study was to evaluate the feasibility of PIVKA-II (protein induced by vitamin K absence or antagonist-II) alone or in combination with α-1 fetoprotein (AFP), as a screening marker for development of HCC. MATERIALS AND METHODS: A case-control study was conducted in 2 hospital wards in Naples. All anti-HCV-positive patients affected by HCC were considered as cases, while consecutive anti-HCV-positive patients without HCC were considered as controls. RESULTS: Overall, 160 patients were enrolled, 56 cases and 104 controls. At the set cut-off of 36 mAU/ml, PIVKA-II was more sensitive (78.6% vs. 60%), but less specific than AFP at the set cut-off of 12 ng/ml (66.3% vs. 77.2%). The negative predictive value of PIVKA in combination with AFP was 93.2%. CONCLUSION: PIVKA II, when combined with AFP, may be considered as a screening test for HCC due to its high negative predictive value. Copyright
BACKGROUND/AIM: Patients affected by liver cirrhosis are at high risk for developing hepatocellular carcinoma (HCC). The aim of this study was to evaluate the feasibility of PIVKA-II (protein induced by vitamin K absence or antagonist-II) alone or in combination with α-1 fetoprotein (AFP), as a screening marker for development of HCC. MATERIALS AND METHODS: A case-control study was conducted in 2 hospital wards in Naples. All anti-HCV-positive patients affected by HCC were considered as cases, while consecutive anti-HCV-positive patients without HCC were considered as controls. RESULTS: Overall, 160 patients were enrolled, 56 cases and 104 controls. At the set cut-off of 36 mAU/ml, PIVKA-II was more sensitive (78.6% vs. 60%), but less specific than AFP at the set cut-off of 12 ng/ml (66.3% vs. 77.2%). The negative predictive value of PIVKA in combination with AFP was 93.2%. CONCLUSION: PIVKA II, when combined with AFP, may be considered as a screening test for HCC due to its high negative predictive value. Copyright
Authors: Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; H Yoshida; S Shiina; M Omata Journal: Cancer Date: 2001-02-01 Impact factor: 6.860
Authors: Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani Journal: Am J Gastroenterol Date: 2006-03 Impact factor: 10.864